(Q34423324)

English

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study (English)

1 reference

Europe PubMed Central

2 August 2017

0 references

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

author name string

Anthony D D'Urzo

1

1 reference

Europe PubMed Central

2 August 2017

Stephen I Rennard

2

1 reference

Europe PubMed Central

2 August 2017

Edward M Kerwin

3

1 reference

Europe PubMed Central

2 August 2017

Victor Mergel

4

1 reference

Europe PubMed Central

2 August 2017

Anne R Leselbaum

5

1 reference

Europe PubMed Central

2 August 2017

Cynthia F Caracta

6

1 reference

Europe PubMed Central

2 August 2017

AUGMENT COPD study investigators

7

1 reference

Europe PubMed Central

2 August 2017

publication date

14 October 2014

1 reference

Europe PubMed Central

2 August 2017

Respiratory Research

1 reference

Europe PubMed Central

2 August 2017

15

1 reference

Europe PubMed Central

2 August 2017

123

1 reference

Europe PubMed Central

2 August 2017

copyright license

Creative Commons Attribution 4.0 International

14 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s12931-014-0123-0

0 references

Minimal clinically important differences in pharmacological trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Impact of night-time symptoms in COPD: a real-world study in five European countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Night-time symptoms: a forgotten dimension of COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Patient adherence in COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Standardisation of spirometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Chronic obstructive pulmonary disease: developing comprehensive management.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213545

6 July 2018

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

1 reference

https://api.crossref.org/works/10.1186%2FS12931-014-0123-0

21 January 2018

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

St. George's Respiratory Questionnaire: MCID

1 reference

https://pubmed.ncbi.nlm.nih.gov/25756831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12931-014-0123-0

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34423324&oldid=1860075360"